Acclarent, a maker of a device for sinus treatments, has raised $35 million in a third round of funding, VentureWire reports (sub required):

Acclarent, based in Menlo Park, Calif., was founded in June 2004 to develop a balloon sinuplasty device as a less invasive way to treat chronic sinusitis. The device is inserted through the nose via a guidewire into the targeted sinus. The balloon is then inflated, enlarging the sinus openings, allowing for normal drainage.

Meritech Capital Partners led the round, joined by Delphi Ventures and existing investors New Enterprise Associates, Versant Ventures, as well as individual investors.